A poisoning incident in a medical enterprise involved 43 people, and 1 person has died

On August 5th, Ogilvy Medical released the "Announcement on the Employee Poisoning Incident of Ogille (Jingmen) Medical Products Co., Ltd.", which was confirmed that the previously passed on the Internet "Ogilvy Medical Safety Safety Cases suspected of major production safety incidents" and "Ao Ao" "U.S. Medical Employees Poisoning and Entering the hospital for rescue".

Ogilvy Medical Announcement stated that some employees of the subsidiary Ogilvy (Jingmen) Medical Products Co., Ltd. (hereinafter referred to as "Jingmen Ome") had symptoms of physical discomfort and were diagnosed as a poisoning incident; after preliminary judgment, the cause of the cause of poisoning was inhaled PET Caused by gluely release of tethaline; the glue is only used in the products customized by PET plastic hard boxes by specific customers of Jingmen Ogille. Jingmen Ogilvy does not involve other products and other production processes of Ogilvy Medical Production.

Ogilvy Medical said that after the incident, the company attached great importance to it, immediately launched an emergency plan, treats the wounded at all costs, and continues to monitor the health status of the rest of the people in the factory area. At the time, after multiple rounds of health testing with historical personnel with the history of the workshop, 43 people had 43 indicators, all of which were treated in the hospital. One of the employees died of acute myocardial infarction during the treatment process. The remaining employees still In treatment, the company is investigating the incident in cooperation with relevant local departments. The specific causes and responsibilities of the incident need to be further verified.

According to the incident's operating performance on Ogilvy Medical, the company stated that the packaging process of PET plastic hard box involved in the incident was the first time to introduce production in the near future, involving a contract amount of about 2.2 million yuan; after preliminary judgment, the incident would not be temporarily for the time being It has a significant impact on the company's production and operation; the company will use this incident as a warning, strengthen management, and eliminate hidden dangers.

However, it is worth noting that Ogilvy Medical did not disclose the specific time of this incident in detail, and whether the announcement time meets the requirements of the letter. In this regard, Ogilvy Medical did not respond to interface news.

Tianyancha shows that Jingmen Ogilvy is a subsidiary of 100%of Ogilvy Medical. The scope of its business permits includes the production of the second type of medical device, the production of the third category of medical device, and the production of medical supplies. In the financial report of Ogilvy Medical, the financial proportion of Jingmen Ogilvy was not specifically mentioned. On August 5, Ogilvy Medical opened by more than 5%.

PET (Polyzhexyate ethylene glycol) is a basic organic raw material for petrochemical and chemical industry. It is also a saturated thermoplastic polymer. That is, under a certain temperature conditions, plastic can soften or melt into arbitrary shapes, and the shape remains unchanged after cooling; this state can be repeated multiple times. This material is mainly used to produce polyester, antifreeze, lubricant, plasticizer, etc., such as beverage bottles and synthetic materials. Recently, "Sprite Farewell to the Green Bottle" also considers its green beverage bottle containing this unused green polytic benzenerite ethylene glycol.

In recent years, because the material is not conducive to environmental protection and is likely to cause potential poisoning risks, domestic regulatory departments usually conduct inspections on the material products. In addition, there are currently cities with the red line of the use of the material. According to the Hainan Daily, in March 2020, the Hainan Provincial Department of Ecology and Environment announced that the "Hainan Province forbidden to produce and sell the use of one -time non -degradable plastic product list (first batch)" will be on December 1, 2020 Starting, it contains polypholic acid ethylene glycol.

Ogilvy Medical has been familiar with the market in recent years because of the new crown business. Its mask and other protective products have achieved good sales in recent years. The company currently has four major wounds and bandaging care, surgery/surgery, infection protection, and combination bags. Series products.

It should be noted that the current polyzhebenate glycols that attract attention are not the main business or product of Ogilvy Medical. The company also mentioned in the announcement that the product involved belongs to the customer's customized series of products, and the material that caused poisoning is only the material used in production and processing.

At present, in addition to employees' poisoning, how to grow after Ogilvy Medical's performance after leaving the mask dividends is also a topic of paying attention to the market. According to the financial report data, from 2018 to 2021, the company's revenue was 2.028 billion yuan, 2.352 billion yuan, 3.834 billion yuan, and 2.926 billion yuan; net profit at home was 228 million yuan, 326 million yuan, 1.158 billion yuan, 4.31 4.31 100 million yuan. In the first quarter of 2022, Ogilvy Medical achieved revenue of 993 million yuan, an increase of 21.02%year -on -year; net profit at home was 158 million yuan, an increase of 35.61%year -on -year.

It can be seen that after the peak of performance in 2020, Ogilvy Medical's current performance is gradually returning to the level before the epidemic. As a main battalion consumable, especially low -value consumables, its profitability is expected to return to the level of 2020 in the short term.

In the secondary market, due to the no longer hot spots of the new crown, Ogilvy's medical stock price has continued to decline in the past two years. The average stock price after 2022 is 14 yuan/share. On February 10, 2020, the company's stock price reached 37.47 yuan/share.

Source: Cover News

- END -